Break-out Sessions

Evidence Live 2013 - Monday 25th March
all sessions
A1 Child Health
Session: TREKK: an initiative to mobilize knowledge on best paediatric emergency clinical care
Terry Klassen
Director, Manitoba Institute of Child Health
25th Mar 2013 - 11:20

The acute care of children in emergency departments has been evolving rapidly over the last 25 years with clinical expertise, training and a growing evidence base as to how to optimally manage these children. Research networks have created new knowledge to guide evidence-based practice in acute respiratory illness, injury and gastroenteritis. However, the care of these children often occurs in an emergency department that is not part of a children’s hospital and hence may not have the same level of access to this new evidence. To address this gap of knowledge translation, Translating Emergency Knowledge for Kids (TREKK) was funded by the Networks of Centers of Excellence program in Canada.

all sessions
A1 Child Health
Session: Challenges in developing an evidence base across children's services
Ruth Gilbert
Professor of Clinical Epidemiology, Institute of Child Health, University College London
25th Mar 2013 - 11:20

Recognising and responding to child maltreatment is an area where paediatricians work hand in hand with statutory child protection and judicial services.  Expert paediatric opinion is often pivotal to decisions about children’s safety and there is growing emphasis on a rigorous evidence base for signs of abuse. However, robust evidence for the core business of child protection services, placement of children in out-of-home care, remains elusive. This lack of evidence contrasts with the growing numbers of children being placed out of home at an earlier age. I will present findings of a systematic review of out of home care and discuss approaches to randomisation and trial design in the context of judicial decisions about children.

all sessions
A1 Child Health
Session: Improving Evidence-based Practice in Neonatology: from India to McMaster
Sourabh Dutta
Associate Professor in Neonatology, McMaster University
25th Mar 2013 - 11:20

I have worked as a faculty member both in India and McMaster University, Canada. I compare my experiences with implementing Evidence-based Practice In Neonatology (EPIN) in the developing and developed world. EBM is all about the “care of individual patients”. In India, high workloads preclude thinking about EPIN at the level of the individual patient. There is lack of internet access at the bedside and ward; and making a trip to the office or home is impractical. Lack of local data on baselines risks, pre-test probabilities, and lack of well conducted studies in developing countries often precludes meaningful calculation of NNT’s and post-test probabilities. In private hospitals, lack of medical insurance and loss of wages results in a demand for unrealistic and quick-fix clinical improvements, even if they are by non-evidence-based remedies. In McMaster, there was widespread awareness about EBM, but tendencies to relegate EPIN to a theoretical exercise limited to journal clubs and not used as a practical tool at the bedside. There was an unwillingness to use data generated elsewhere to the extent that it hampered introduction of effective treatment options. As in India, there was a reluctance to make estimates about baseline risks or pre-test probabilities in individual patients. In both setups, physicians preferred published evidence-based guidelines and protocols.

Chaired by
Terence Stephenson
Nuffield Professor of Child Health, University College London
all sessions
A2 Building blocks of healthcare guidance
Session: Using health technology assessments to identify, evaluate and combine research evidence
Peter Davidson
Director of NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC)
25th Mar 2013 - 11:20

Peter is Director of NETSCC, HTA (Health Technology Assessment programme) and was first appointed in 2006. He has also led the HTA Clinical Trials work stream and was series editor of the Health Technology Assessment journal. The HTA Programme produces independent research about the effectiveness of different healthcare treatments and tests for those who use, manage and provide care in the NHS. It identifies the most important questions that the NHS needs the answers to by consulting widely with these groups, and commissions the research it thinks is most important through different funding routes.

all sessions
A2 Building blocks of healthcare guidance
Session: Key tools for decision makers - how to find and interpret systematic reviews
Martin Burton
Director of the UK Cochrane Centre
25th Mar 2013 - 11:20

Martin Burton is director of the UK Cochrane Centre which has special responsibility for Cochrane entities and contributors in the UK, Ireland and the Middle East.  It has a Branch in Bahrain. Cochrane Centres help to maintain and improve the quality and usefulness of Cochrane reviews through the provision of learning, development and support to Cochrane entities.

The center, under Martin’s direction, It has had an important role as a knowledge broker and is developing and implementing a key programme of engagement with UK stakeholders to reflect the very substantial overall support given by the UK Government, through the NIHR, to Cochrane activities.  At the same time, it seeks to develop new engagement activities that will maximise the quality and relevance of Cochrane outputs to health and social care throughout the world.

all sessions
A2 Building blocks of healthcare guidance
Session: Building blocks of healthcare guidance:increasing access to trial data and systematic reviews of individual participant data.
Lesley Stewart
Director of Centre for Reviews and Dissemination (CRD)
25th Mar 2013 - 11:20

In addition to her role as Centre Director, Lesley maintains research interests in the conduct and methodological development of systematic reviews, particularly individual participant data (IPD) meta-analysis. She is currently principal investigator (PI) of a project funded by Yale University to carry out an IPD meta-analysis of a controversial product used in spinal surgery, including scrutiny and re-analysis of clinical trial IPD deposited with Yale by the manufacturer.

She is also PI of a three year MRC funded project evaluating the utility of various approaches to IPD synthesis, and PhD supervisor of an IPD meta-analysis to identify the patterns of risk in febrile neutropenia. Lesley has also overseen and been actively involved in the development of PROSPERO, an international prospective register of systematic reviews which CRD launched in February 2011.

Chaired by
David Tovey
Editor in Chief, The Cochrane Library
all sessions
A3 Public-patient involvement
Session: The Patient Paradox
Margaret McCartney
GP in Glasgow and author of the book The Patient Paradox
25th Mar 2013 - 11:20

Here's my problem. If I have a patient who is at high risk of premature death - say, who is a smoker, has heart disease, is under enormous economic stress, and who has a new diagnosis of depression; it will take three months, at least, for him to start evidence based cognitive treatments. This is if he can remember to fill in the right forms and get through on the phone to confirm he still wants it. Contrast this with a patient who is sent an appointment for breast screening, and is diagnosed and treated for ductal carcinoma in situ. My first patient needs to become a patient yet can't, and is inadequately treated; my female patient - who was initially quite well - probably isn't going to benefit from a diagnosis she was inadequately warned about, becomes a patient, and is likely overtreated. How can the public make sense of a system which often prioritises the wants of the well beyond the needs of the sick - and why have we failed to explain or change this unfairness?

all sessions
A3 Public-patient involvement
Session: Who holds the power in prioritising health care research….time for change?
Sally Crowe
Co Chair James Lind Alliance
25th Mar 2013 - 11:20

This presentation will focus on the dynamics and balance of power in processes for prioritising research. It will consider what patients, carers and the public (and clinicians) can contribute to research prioritisation, and how they can be involved meaningfully using the James Lind Alliance model of Priority Setting Partnerships as an example. As the James Lind Alliance prepares to move to the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) this presentation will reflect on the last 6 years experience of research priority setting in many disease areas, involving many different people. What has worked? What hasn’t? How important has the values base of the JLA and Priority Setting Partnerships model influenced the process, and has the balance of power really been redressed using this approach?

all sessions
A3 Public-patient involvement
Session: The role of patient experience in driving health care improvement and innovation
Martine Price
Head of Patient Experience, Taunton and Somerset NHS Foundation Trust
25th Mar 2013 - 11:20

Improvement often focuses on clinical systematic processes to improve outcomes. By involving patients and their families and using tried and tested interventions you improve both the processes and the patient experience of care. Patient experience is about putting the patient at the heart of quality improvement.

This presentation gives an overview of Musgrove Park Hospital’s journey of improvement and how an Improvement Network led by clinicians at the front line is driving significant improvements in clinical outcomes, the experience of both patients and staff and at the same time driving efficiency.

Chaired by
Sir Iain Chalmers
James Lind Initiative, Oxford, UK
all sessions
Workshop & Poster Sessions
Session: Oral Posters & Exhibitions
25th Mar 2013 - 11:20

Oral Poster Sessions

The East room will host Oral poster sessions and a poster gallery. Presenters will be sharing their research with a five minute presentation and two minute for Q & A, these presentations will be supported by the poster which will also be on display throughout the whole event.

all sessions
B1 Medical Devices
Session: Investigating the evidence for medical devices
Deb Cohen
Assistant Editor, BMJ
25th Mar 2013 - 16:10

Deb Cohen is a medically qualified reporter and BMJ editor with an extensive international contacts book and a proven track record in hard hitting health and science investigations. As a reporter and commissioning editor of the BMJ, Deborah will talk about her work which has focused mainly on health including pharmaceuticals, genetics, nutrition, medical implants, pseud-scientific claims and food. As well as writing for print, she has co-produced documentaries and reported for Newsnight and been interviewed many times by the international media and explained complex subjects to a non-specialist audience following the publication of investigations.

all sessions
B1 Medical Devices
Session: The IDEAL Collaboration: helping to improve research quality in surgery and other complex interventions
Peter McCulloch
Clinical Reader in Surgery, University of Oxford
25th Mar 2013 - 16:10

IDEAL is a descriptive framework for the stages of surgical innovation. The IDEAL Collaboration is working on ways to improve the reliability, relevance and fundability or research in surgery, medical devices and other areas of complex information.

Why IDEAL? Because surgery is procedure-based, it presents challenges to gathering, reporting, and applying sound evidence that are not seen in medicine. These challenges are faced by everyone involved in producing and using evidence: researchers, journal editors, clinicians, device manufacturers, and regulators.

What are the stages of surgical innovation as described by IDEAL? First, there is an Idea or Innovation, which then undergoes Development and Exploration, and subsequently Assessment and Long-term Studies). Within this framework are recommendations at each stage for methodology, reporting, and, where applicable, regulation.

all sessions
B1 Medical Devices
Session: "Are patients just pound signs?": perspectives of people with failed metal on metal hip implants
Pauline McCormack
Research Associate, Newcastle University
25th Mar 2013 - 16:10

The ASR metal-on-metal (MoM) hip replacement manufactured by DePuy Orthopaedics (a subsidiary of Johnson & Johnson) and implanted into almost 100,000 people worldwide, has failed in unprecedented numbers.  The implant is currently the subject of legal dispute worldwide.  In focus groups that we conducted with MoM hip patients they asked “who knew what and when”?  They recount lives disrupted and ruined by the health problems caused through having a faulty implant and the attendant anxiety about possible long-term, systemic health issues.

This talk examines the response of UK stakeholders to the DePuy ASR hip implant failure and asks if, in order to prevent future occurrences, a more precautionary approach should be taken in light of data which indicates potential problems.  We reflect on the patients’ most profound question, “could all this have been avoided”?

Chaired by
Carl Heneghan
Director, Centre for Evidence-Based Medicine, University of Oxford
all sessions
B2 Diagnostics
Session: The Challenges of Evidence-Based Diagnostics: A NICE Perspective
Nick Crabb
Associate Director, Diagnostics Assessment Programme, NICE
25th Mar 2013 - 16:10

The presentation will briefly introduce the programmes at NICE where diagnostic technologies are evaluated. In the NICE diagnostics assessment programme, and in clinical guidelines, cost effectiveness methodology is deployed. In the NICE medical technologies evaluation programme, a simpler cost consequences methodology is adopted. Some of the general challenges of diagnostics assessment will then be presented before moving on to evidence considerations. Examples from published NICE guidance will also be given to illustrate both the cost effectiveness and cost consequences methodologies. The presentation will conclude with consideration of forward priorities for the further development of evidence based diagnostics.

all sessions
B2 Diagnostics
Session: Evidence-Based Monitoring: Which test? How often?
Paul Glasziou
Professor, Centre for Research in Evidence-Based Practice, Bond University, Australia.
25th Mar 2013 - 16:10

Monitoring and management of long term illness is an important and costly element of health care It accounts for around 80% of GP consultations, and a substantial proportion of laboratory testing. Despite the high workload and costs, monitoring has been neglected as an area for research and guidance. And the little evidence that we have has not been widely applied. For example, despite clear evidence that daily glucose monitoring is not warranted in type 2 diabetes, the global costs of glucose monitoring strips alone exceed $1Billion per year.

The clinical monitoring for several other conditions - including lipid management, blood pressure management, telemonitoring and HbA1c testing - do not align with the current evidence. However, optimal monitoring requires identify the best monitoring test, an appropriate schedule, and the optimal adjustments for out-of-range measurements. Current randomised trials of monitoring showed a mixed pattern of effects, but few appear to have optimized monitoring protocols prior to the trial.

all sessions
B2 Diagnostics
Session: Why are systematic reviews of diagnostic tests needed but so complicated?
Jon Deeks
Professor of Biostatistics, University of Birmingham
25th Mar 2013 - 16:10

Evaluations of diagnostic tests need to consider a) how tests impact on patients, b) their role and position in clinical pathways, c) the alternatives with which they must be compared. 

In this presentation we will consider how systematic reviews of test accuracy are a necessary part of a test evaluation but not always sufficient to predict the impact of a test on patients, when it is important to assess other aspects of test performance, and how our ability to evaluate test accuracy is hindered by poor and inadequate primary research.

Key references:

  • Ferrante di Ruffano et al. How do diagnostic tests change patient health? A framework for understanding test-treat interventions.  BMJ 2012;344:e686. doi: 10.1136/bmj.e686.
  • Takwoingi Y et al.  Empirical evidence of the importance of comparative studies of diagnostic test accuracy. Ann Intern Med.  In press.
  • Deeks et al (eds).  Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Available from: http://srdta.cochrane.org/
Chaired by
Patrick M.M. Bossuyt
Professor of Clinical Epidemiology, University of Amsterdam
all sessions
B3 Evidence in low-income settings
Session: Challenges delivering evidence-based practice in conflict zones
Khamis Elessi
Head of the Gaza Evidence-Based Medicine Unit, Islamic University
25th Mar 2013 - 16:10

The overall goal of my talk is to provide you with the most important health indicators in Palestine, particularly the Gaza Strip.

I’ll shed some light on key aspects of medical education in Gaza, including the medical schools, their curricula, languages, and facilities available to students, such as medical libraries and journals. Characteristics of doctors such as their education, place of graduation and some quality issues will be discussed.

Finally, I will talk about the establishment of the first EBM unit in Palestine at the IUG, the context in which it is evolving, its accomplishments to date, plans for the future and the challenges we face.

all sessions
B3 Evidence in low-income settings
Session: Cochrane and policy
Catherine Gallagher
Director, Cochrane Collaboration College for Policy
25th Mar 2013 - 16:10

Catherine is Director of the Cochrane Collaboration College for Policy at George Mason University, just outside of Washington, D.C. The mission of the Cochrane Policy College is to provide policy-makers with rigorous evidence as they broach health and social policy decisions and appropriations.

all sessions
B3 Evidence in low-income settings
Session: High quality randomised controlled trials in fluid resuscitation sub-saharan Africa: it is possible?
Professor Kathryn Maitland
Professor, KEMRI-Wellcome Trust Research Programme
25th Mar 2013 - 16:10

FEAST, a controlled trial of fluid resuscitation, in children aged >60 days with severe febrile illness showed that early rapid fluid resuscitation (boluses) increased absolute 48-hour mortality by 3.3% versus controls (no bolus). The results, published in NEJM last year, challenged the primacy of bolus resuscitation as a life-saving intervention in resource-limited settings, and also raised questions on fluid resuscitation elsewhere. My talk will cover the background to the FEAST trial, work leading up, results and subsequent response to it publication. In addition, further analysis on putative modes of death, according to terminal clinical events.

Chaired by
Ginny Barbour
Chief Editor, PLoS Medicine
all sessions
Workshop & Poster Sessions
Session: Oral & Guided Poster Sessions
25th Mar 2013 - 16:10

Oral Poster Sessions

The East room will host Oral poster sessions and a poster gallery. Presenters will be sharing their research with a five minute presentation and two minute for Q & A, these presentations will be supported by the poster which will also be on display throughout the whole event.

Guided Poster Sessions

... continued from Coffee break

Guided poster sessions will run during break times. Posters will be grouped by area of interest, where authors will be taken through a session by a leading expert in the field allowing each two minutes to share their research project.

Evidence Live 2013 - Tuesday 26th March
all sessions
C1 Modelling in healthcare
Session: How modelling in health care influences decision making: the bottom line
Ken Stein
Professor of Public Health, University of Exeter
26th Mar 2013 - 11:10

Want to know how quality of life estimates in health technology assessment, synthesis of qualitative research, and the use of decision analytic modelling support planning and management in the NHS.

all sessions
C1 Modelling in healthcare
Session: When favourable economics doesn’t lead to implementation : Cascade Testing for Familial Hypercholesterolaemia an example
Steve Humphries
BHF Professor of Cardiovascular Genetics, University College London
26th Mar 2013 - 11:10

In the NICE Familial Hypercholesterolaemia (FH) guidelines CG71 published in August 2008, Cascade Testing was strongly recommended using DNA mutation information where it was available, or by determining levels of LDL-cholesterol in families where it was not. The NICE recommendations were based on evidence from extensive experience of Cascade Testing in Holland and in the UK, demonstrating the feasibility, acceptability and cost effectiveness of the approach, as well as modelling based on the available UK data which estimated the cost per quality adjusted life year gained is £2,111. Disappointingly, the 2010 RCP UK-wide audit of the management of FH in 118 lipid clinics (2471 patient notes) found that while Cascade Testing had been initiated in almost 75% of the notes examined, less than half of the proband’s children and less than 40% of their siblings had been contacted. DNA testing was only widely available in Wales, Scotland and Northern Ireland, highlighting the lack of funding under current commissioning arrangements. The data suggests that to be most effective, Cascade Testing requires education of commissioners and GPs, the establishment of specific FH clinics, and the setting up of a nationwide database to ensure effective linking of distant families.

all sessions
C1 Modelling in healthcare
Session: The role of modelling in health care
Klim McPherson
Visiting Professor of Public Health Epidemiology
26th Mar 2013 - 11:10

While risk factor prevalences vary and change with time it is difficult to anticipate the change in disease that will result without accurately modelling the epidemiology. When detailed study of the prevalence of obesity, tobacco and salt intake, for example, are studied clear patterns emerge that can be extrapolated into the future. These can give rise to probability distributions of these risk factors across age, sex, ethnicity, social class groups etc into the future. Micro simulation of individuals from defined populations (eg England 2012) can then estimate disease incidence, prevalence, death and quality of life. Thus future health and other needs can be estimated and interventions on these risk factors can be simulated for their population effect. Thus health policy can be better determined by a realistic characterisation of public health.  The Foresight microsimulation modelling of the National Heart Forum (UK Health Forum) will be described.

Chaired by
Tobias Kurth
Director of Research, INSERM
all sessions
C2 Latest in publishing
Session: Update from the Cochrane Collaboration: what's new, and what it will look like in 10 years?
David Tovey
Editor in Chief, The Cochrane Library
26th Mar 2013 - 11:10

Despite the increasing strategic importance of evidence in medicine, the future of publishing has probably never looked so uncertain. The inexorable progress of open access should mean that within a few years most journals will not sit behind pay walls, opening up evidence to everyone. We will see increasing innovation in terms of technology capabilities, with new tech start-ups challenging traditional publishers as they seek to bring knowledge to readers in different and more accessible ways. We will see an expansion in data availability with research being made available in open access databases and repositories and the growth of secondary research based on these data. We might even see the end of data being hidden by trial sponsors so that we can all achieve a more realistic understanding of the effects of healthcare interventions. All this is what we can anticipate, but there will be innovations and changes that seem unimaginable today. I aim to explore some of the possibilities and how this might change clinical practice, evidence synthesis and the development of guidelines.

all sessions
C2 Latest in publishing
Session: Delivering open access publishing: lessons learnt from BMJ Open
Trish Groves
Deputy Editor, BMJ and Editor in Chief, BMJ Open
26th Mar 2013 - 11:10

BMJ Open is an online-only general medical journal. Along with providing completely open peer review and open access to all articles, BMJ Open is helping authors to deposit the raw data from their studies. How does this work? Why aren't other journals doing this? Who's sharing data? And what are the pros and cons of data sharing in research that involves real patients?

all sessions
C2 Latest in publishing
Session: What are the new possibilities in publishing that can emerge from the PLOS model?
Ginny Barbour
Chief Editor, PLoS Medicine
26th Mar 2013 - 11:10

The advent of the internet is enabling scientific and medical publishing to change radically. Not only has the liberation from a print-based medium allowed a change in how journals are accessed (and by whom) and the development of new business models for publishing, but in addition the use of licenses developed by Creative Commons is enabling innovative ways of reusing content. In addition, the change from journal-based metrics to article-based metrics is catalysing a change in assessment and understanding of the impact of research.

Chaired by
Howard Bauchner
Editor-in-Chief of JAMA
all sessions
C3 Best research papers of all time
Session: Chaired by Helen MacDonald, Editor of Student BMJ
26th Mar 2013 - 11:10
all sessions
Workshop & Poster Sessions
Session: Oral Posters & Exhibitions
26th Mar 2013 - 11:10

Oral Poster Sessions

The East room will host Oral poster sessions and a poster gallery. Presenters will be sharing their research with a five minute presentation and two minute for Q & A, these presentations will be supported by the poster which will also be on display throughout the whole event.

all sessions
D1 Evidence aid
Session: The lack of an evidence base for humanitarian interventions
Les Roberts
Director, Program on Forced Migration and Health
26th Mar 2013 - 15:00

The relief community attributes great success to the growing international humanitarian efforts associated with most disasters and prolonged humanitarian crises. Indeed, the frequency of very high mortality events, and the number of protracted conflicts has diminished since the end of the cold war. Certain elements of humanitarian relief, such as measles immunization appear to have contributed to the positive trends. Yet, many established guidelines and practices appear to have no published evidence base and few trials of any kind have been conducted in crisis situations. Pressure from funders, short funding cycles, and the melding of political and humanitarian agendas all conspire to undermine accountability efforts within the relief community. A review of the evidence base for the SPHERE Standards and some examples of counter-intuitive evaluation findings will be presented.

all sessions
D1 Evidence aid
Session: Innovative methods to gather health care access, cost and data quality in humanitarian emergencies
Paul Spiegel
Deputy Director of the Division of Programme Support and Management at the United Nations High Commissioner for Refugees (UNHCR)
26th Mar 2013 - 15:00

Much of the evidence for humanitarian response comes from refugee camps in low income countries. However, during the past few decades, more and more humanitarian crises are occurring in non-camp settings in middle income countries (e.g. the current Syrian crisis). Two examples of innovative methods to measure access and quality of care in these settings will be presented-balance score card for primary health care clinics and prospective surveillance for health care access and costs. Finally, the web-based “Twine” information system” will be presented to show the possibilities of sharing information to make decisions at the field level as well as advocacy for funding at the global level.

all sessions
D1 Evidence aid
Session: The growing role and impact of Evidence Aid, and its 10-year direction
Bonnix Kayabu
Evidence Aid Co-ordinator at the Centre for Global Health
26th Mar 2013 - 15:00

The Cochrane Collaboration’s Evidence Aid project was established by The Cochrane Collaboration following the tsunami in the Indian Ocean in December 2004. It uses knowledge from Cochrane Reviews and other systematic reviews to provide reliable, up-to-date evidence on interventions that might be considered in the context of natural disasters and other major healthcare emergencies. Evidence Aid seeks to highlight which interventions work, which don’t work, which need more research, and which, no matter how well meaning, might be harmful; and to provide this information to agencies and people planning for, or responding to, disasters.

Chaired by
Mike Clarke
Evidence Aid; Professor/Director of MRC Methodology Hub, Queens University Belfast
all sessions
D2 Dealing with hidden data - A new paradigm for systematic reviews?
Session: Selective publication and reporting: not things of the past
An-Wen Chan
Phelan Scientist, Women's College Research Institute, University of Toronto
26th Mar 2013 - 15:00

The past two decades have been plagued by compelling evidence of patient harms arising from suppression of unfavourable clinical trial results. Despite the implementation of important initiatives to address biased reporting, the trial literature continues to represent a distorted picture of the efficacy and harms of clinical interventions. Additional substantive solutions are needed to ensure that patient care is guided by the totality of existing evidence rather than a select subset of misinformation.

all sessions
D2 Dealing with hidden data - A new paradigm for systematic reviews?
Session: Bias in neuraminidase inhibitors - are traditional systematic review methods defunct?
Tom Jefferson
Editor Cochrane Acute Respiratory Infections Group
26th Mar 2013 - 15:00

A recent survey has shown that only 10% of Cochrane reviews make serious efforts to search for and include unpublished material. Such an approach is no longer tenable as a growing body of evidence shows that reliance of wholly or mostly published data introduces bias in the conclusions of a review and because in the last 2 years the EMA has released over 1.6 million pages of regulatory information.


Tom Jefferson will present and discuss some of these issue on the basis of the oseltamivir (Tamiflu) review, starting with the story of how his team realised their previous Cochrane review on Tamiflu were biased and how they went about addressing the problem.

Chaired by
Doug Altman
Director, Centre for Statistics in Medicine, Oxford
all sessions
D3 Engaging with the internet
Session: The growing role of social media to facilitate evidence-based practice
James Quekett
Doctors.net.uk
26th Mar 2013 - 15:00

Knowledge and evidence is insufficient in changing practice, the uptake of evidence into clinical practice is complex and requires the clinician to be able to place that knowledge within the context of their own work. Producing a guideline is simply not enough. Clinicians need to discuss with each other the 'best fit' for any new evidence and whether they need to do things differently as a result. There may also be a discussion on whether or not the evidence itself is valid. This requires social interaction which has traditionally been done in the face to face environment but now may occur online within social media.

all sessions
D3 Engaging with the internet
Session: Anarchism, Punk and EBM
Jon Brassey
TRIP Database Ltd & Public Health Wales
26th Mar 2013 - 15:00

Bringing sex, drugs and rock n roll to the world of EBM! This presentation will link the principles of anarchism and punk to systematic reviews and specifically Cochrane. It will highlight a number of significant problems with the current situation and make some suggestions for changes that are long overdue.  The presentation will finish with the question 'Does Cochrane do more harm than good?'

Chaired by
Luisa Dillner
doc2doc
all sessions
Workshop & Poster Sessions
Session: Guided Poster Sessions
26th Mar 2013 - 15:00

 

Guided Poster Sessions

... continued from Coffee break

Guided poster sessions will run during break times. Posters will be grouped by area of interest, where authors will be taken through a session by a leading expert in the field allowing each two minutes to share their research project.